We are live on ! Find out more
PRVL

Prevail Therapeutics Inc. Common Stock
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

Back to rankings

93 hedge funds and large institutions have $648M invested in Prevail Therapeutics Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 16 increasing their positions, 27 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

115% more capital invested

Capital invested by funds: $302M → $648M (+$346M)

71% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 24

22% more funds holding

Funds holding: 76 → 93 (+17)

41% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 27

77% less call options, than puts

Call options by funds: $3.68M | Put options by funds: $15.8M

Holders
93
Holders Change
+17
Holders Change %
+22.37%
% of All Funds
1.65%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
41
Increased
16
Reduced
27
Closed
24
Calls
$3.68M
Puts
$15.8M
Net Calls
-$12.1M
Net Calls Change
-$12.1M

Top Buyers

Rank Fund Capital Flow
1
AAM
Alpine Associates Management
Florida
+$10.9M
2
TAL
TIG Advisors LLC
New York
+$8.99M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$7.55M
4
Millennium Management
Millennium Management
New York
+$6.64M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$3.52M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$19.5M
2
HighTower Advisors
HighTower Advisors
Illinois
-$11.5M
3
BlackRock
BlackRock
New York
-$9.81M
4
Morgan Stanley
Morgan Stanley
New York
-$7.86M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$319M – – –
Citadel Advisors
2
Citadel Advisors
Florida
$55.8M +$45.9K +3,622 +0.2%
BlackRock
3
BlackRock
New York
$28.4M -$9.81M -773,808 -39%
BC
4
Boxer Capital
California
$25.9M – – –
AAM
5
Alpine Associates Management
Florida
$19.8M +$10.9M +857,705 New
Vanguard Group
6
Vanguard Group
Pennsylvania
$19.3M +$878K +69,274 +9%
TAL
7
TIG Advisors LLC
New York
$16.4M +$8.99M +709,282 New
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$13.8M -$5.98M -471,946 -44%
Alyeska Investment Group
9
Alyeska Investment Group
Illinois
$13.7M +$7.55M +595,553 New
Millennium Management
10
Millennium Management
New York
$13.6M +$6.64M +523,965 +794%
Bank of America
11
Bank of America
North Carolina
$12.5M +$749K +59,074 +12%
Goldman Sachs
12
Goldman Sachs
New York
$6.77M +$3M +237,045 +420%
Balyasny Asset Management
13
Balyasny Asset Management
Illinois
$6.4M +$3.52M +277,374 New
PAMP
14
Polar Asset Management Partners
Ontario, Canada
$6.16M +$3.38M +266,960 New
C
15
Chescapmanager
Maryland
$5.89M +$3.24M +255,407 New
State Street
16
State Street
Massachusetts
$5.55M -$156K -12,316 -5%
BHMP
17
Bardin Hill Management Partners
New York
$4.77M +$2.62M +206,867 New
GCIA
18
Gabelli & Co Investment Advisers
New York
$4.75M +$2.61M +205,800 New
Man Group
19
Man Group
United Kingdom
$4.61M +$2.53M +200,000 New
GF
20
Gabelli Funds
New York
$4.19M +$2.3M +181,442 New
Geode Capital Management
21
Geode Capital Management
Massachusetts
$3.63M -$166K -13,061 -8%
Northern Trust
22
Northern Trust
Illinois
$3.59M -$37.7K -2,974 -2%
NM
23
Newtyn Management
New York
$3.54M +$1.95M +153,617 New
GCL
24
Glazer Capital LLC
New York
$3.37M +$1.85M +145,915 New
QF
25
QVT Financial
New York
$3.08M – – –
1
2 3 4 5

PRVL Hedge Fund Activity: Q4 2020 in Review

93 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q4 2020, worth a combined $648M — up 115% from $302M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new PRVL positions and 24 closed out — a net gain of 17 holders — while 16 added to existing stakes and 27 trimmed.

The largest buyer was Alpine Associates Management, opening a new position worth an estimated $10.9M. The largest seller was RA Capital Management, exiting entirely with an estimated $19.5M sold.

  • 93 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q4 2020, up from 76 in Q3 2020.
  • Funds reported $648M of Prevail Therapeutics Inc. Common Stock stock for Q4 2020, up 115% quarter-over-quarter.
  • 41 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q4 2020 and 24 closed out, a net change of +17 holders.
  • The largest Prevail Therapeutics Inc. Common Stock buyer in Q4 2020 was Alpine Associates Management, an estimated $10.9M added.
  • The largest Prevail Therapeutics Inc. Common Stock seller in Q4 2020 was RA Capital Management, an estimated $19.5M sold.

Based on aggregated 13F filings for Q4 2020.